BeOne Medicines Ltd. (NASDAQ:ONC) is one of the best-performing European stocks to invest in, with promising Phase 1/2 results for sonrotoclax in mantle cell lymphoma. The trial showed clinically relevant responses and secondary goal achievements. The company plans to seek approval from regulatory agencies, including the FDA and China’s NMRA. BeOne Medicines Ltd. specializes in oncology medicines for blood cancers and solid tumors.

Read more at Yahoo Finance: BeOne Medicines (ONC) Reports Positive Phase 1/2 Results for Sonrotoclax in MCL